Vistusertib,AZD4547,Capivasertib,Sapitinib,Selumetinib,Vandetanib,durvalumab,savolitinib,Olaparib
astrazeneca,sanofi,hutchmed,merck,otsuka
['durva', 'biomarker']
the #oncoalerttoptweet day1 of #asco23 tweet by our oncoalert faculty ctdna tumor fraction continue to accumulate data as biomarker. the safir 2 study from and group shown this in durvalumab, with survival outcomes. best 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨